Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

Paul Y Takahashi, Euijung Ryu, Jyotishman Pathak, Gregory D. Jenkins, Anthony Batzler, Matthew A. Hathcock, John Logan Black, Janet E Olson, James R Cerhan, Suzette J Bielinski

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. The aim was to determine the association of CYP2D6 phenotype with the risk of hospitalization or an emergency department (ED) visit among a group of primary care patients. Methods: In this study, 929 adult patients underwent CYP2D6 testing. The primary outcome was risk of hospitalization or an ED visit from January 2005 through September 2014. CYP2D6 genotypes were interpreted as 1 of 7 clinical phenotypes, from ultrarapid to poor metabolizer, and patients with the extensive metabolizer phenotype were used as the reference group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for finding the association of CYP2D6 phenotypes with the risk of hospitalization or an ED visit by using Cox proportional hazard models and adjusting for age and sex. Results: The median age was 49 years (interquartile range, 46–52 years); 74% of patients had 3 or fewer chronic conditions, 285 had at least 1 hospitalization, and 496 had at least 1 ED visit. The risk of hospitalization was higher among patients who were ultrarapid metabolizers compared to extensive metabolizers (47% vs 30%; HR, 1.69; 95% CI, 1.11–2.57), as was the risk of an ED visit (62% vs 49%; HR, 1.50; 95% CI, 1.05–2.14). For poor metabolizers compared to extensive metabolizers, there was no difference in the risk of hospitalization (HR, 0.95; 95% CI, 0.58–1.56), but there was an increase in the risk of an ED visit (HR, 1.38; 95% CI, 0.96–1.98) (the difference was not statistically significant). Conclusion: We found an increased risk of hospitalization or an ED visit among ultrarapid compared to extensive CYP2D6 metabolizers. Further research identifying the mechanisms of the association and ultimate clinical utility is warranted.

Original languageEnglish (US)
Pages (from-to)39-47
Number of pages9
JournalPharmacogenomics and Personalized Medicine
Volume10
DOIs
StatePublished - Feb 14 2017

Fingerprint

Cytochrome P-450 CYP2D6
Hospitalization
Hospital Emergency Service
Confidence Intervals
Phenotype
Environmental Exposure
Proportional Hazards Models
Primary Health Care
Genotype
Health

Keywords

  • Cohort study
  • Emergency department
  • Hospitalization
  • Pharmacogenomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. / Takahashi, Paul Y; Ryu, Euijung; Pathak, Jyotishman; Jenkins, Gregory D.; Batzler, Anthony; Hathcock, Matthew A.; Black, John Logan; Olson, Janet E; Cerhan, James R; Bielinski, Suzette J.

In: Pharmacogenomics and Personalized Medicine, Vol. 10, 14.02.2017, p. 39-47.

Research output: Contribution to journalArticle

@article{4c6b74ef289140ec83a538d7c13835bf,
title = "Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6",
abstract = "Background: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. The aim was to determine the association of CYP2D6 phenotype with the risk of hospitalization or an emergency department (ED) visit among a group of primary care patients. Methods: In this study, 929 adult patients underwent CYP2D6 testing. The primary outcome was risk of hospitalization or an ED visit from January 2005 through September 2014. CYP2D6 genotypes were interpreted as 1 of 7 clinical phenotypes, from ultrarapid to poor metabolizer, and patients with the extensive metabolizer phenotype were used as the reference group. The hazard ratios (HRs) and 95{\%} confidence intervals (CIs) were estimated for finding the association of CYP2D6 phenotypes with the risk of hospitalization or an ED visit by using Cox proportional hazard models and adjusting for age and sex. Results: The median age was 49 years (interquartile range, 46–52 years); 74{\%} of patients had 3 or fewer chronic conditions, 285 had at least 1 hospitalization, and 496 had at least 1 ED visit. The risk of hospitalization was higher among patients who were ultrarapid metabolizers compared to extensive metabolizers (47{\%} vs 30{\%}; HR, 1.69; 95{\%} CI, 1.11–2.57), as was the risk of an ED visit (62{\%} vs 49{\%}; HR, 1.50; 95{\%} CI, 1.05–2.14). For poor metabolizers compared to extensive metabolizers, there was no difference in the risk of hospitalization (HR, 0.95; 95{\%} CI, 0.58–1.56), but there was an increase in the risk of an ED visit (HR, 1.38; 95{\%} CI, 0.96–1.98) (the difference was not statistically significant). Conclusion: We found an increased risk of hospitalization or an ED visit among ultrarapid compared to extensive CYP2D6 metabolizers. Further research identifying the mechanisms of the association and ultimate clinical utility is warranted.",
keywords = "Cohort study, Emergency department, Hospitalization, Pharmacogenomics",
author = "Takahashi, {Paul Y} and Euijung Ryu and Jyotishman Pathak and Jenkins, {Gregory D.} and Anthony Batzler and Hathcock, {Matthew A.} and Black, {John Logan} and Olson, {Janet E} and Cerhan, {James R} and Bielinski, {Suzette J}",
year = "2017",
month = "2",
day = "14",
doi = "10.2147/PGPM.S114211",
language = "English (US)",
volume = "10",
pages = "39--47",
journal = "Pharmacogenomics and Personalized Medicine",
issn = "1178-7066",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

AU - Takahashi, Paul Y

AU - Ryu, Euijung

AU - Pathak, Jyotishman

AU - Jenkins, Gregory D.

AU - Batzler, Anthony

AU - Hathcock, Matthew A.

AU - Black, John Logan

AU - Olson, Janet E

AU - Cerhan, James R

AU - Bielinski, Suzette J

PY - 2017/2/14

Y1 - 2017/2/14

N2 - Background: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. The aim was to determine the association of CYP2D6 phenotype with the risk of hospitalization or an emergency department (ED) visit among a group of primary care patients. Methods: In this study, 929 adult patients underwent CYP2D6 testing. The primary outcome was risk of hospitalization or an ED visit from January 2005 through September 2014. CYP2D6 genotypes were interpreted as 1 of 7 clinical phenotypes, from ultrarapid to poor metabolizer, and patients with the extensive metabolizer phenotype were used as the reference group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for finding the association of CYP2D6 phenotypes with the risk of hospitalization or an ED visit by using Cox proportional hazard models and adjusting for age and sex. Results: The median age was 49 years (interquartile range, 46–52 years); 74% of patients had 3 or fewer chronic conditions, 285 had at least 1 hospitalization, and 496 had at least 1 ED visit. The risk of hospitalization was higher among patients who were ultrarapid metabolizers compared to extensive metabolizers (47% vs 30%; HR, 1.69; 95% CI, 1.11–2.57), as was the risk of an ED visit (62% vs 49%; HR, 1.50; 95% CI, 1.05–2.14). For poor metabolizers compared to extensive metabolizers, there was no difference in the risk of hospitalization (HR, 0.95; 95% CI, 0.58–1.56), but there was an increase in the risk of an ED visit (HR, 1.38; 95% CI, 0.96–1.98) (the difference was not statistically significant). Conclusion: We found an increased risk of hospitalization or an ED visit among ultrarapid compared to extensive CYP2D6 metabolizers. Further research identifying the mechanisms of the association and ultimate clinical utility is warranted.

AB - Background: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. The aim was to determine the association of CYP2D6 phenotype with the risk of hospitalization or an emergency department (ED) visit among a group of primary care patients. Methods: In this study, 929 adult patients underwent CYP2D6 testing. The primary outcome was risk of hospitalization or an ED visit from January 2005 through September 2014. CYP2D6 genotypes were interpreted as 1 of 7 clinical phenotypes, from ultrarapid to poor metabolizer, and patients with the extensive metabolizer phenotype were used as the reference group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for finding the association of CYP2D6 phenotypes with the risk of hospitalization or an ED visit by using Cox proportional hazard models and adjusting for age and sex. Results: The median age was 49 years (interquartile range, 46–52 years); 74% of patients had 3 or fewer chronic conditions, 285 had at least 1 hospitalization, and 496 had at least 1 ED visit. The risk of hospitalization was higher among patients who were ultrarapid metabolizers compared to extensive metabolizers (47% vs 30%; HR, 1.69; 95% CI, 1.11–2.57), as was the risk of an ED visit (62% vs 49%; HR, 1.50; 95% CI, 1.05–2.14). For poor metabolizers compared to extensive metabolizers, there was no difference in the risk of hospitalization (HR, 0.95; 95% CI, 0.58–1.56), but there was an increase in the risk of an ED visit (HR, 1.38; 95% CI, 0.96–1.98) (the difference was not statistically significant). Conclusion: We found an increased risk of hospitalization or an ED visit among ultrarapid compared to extensive CYP2D6 metabolizers. Further research identifying the mechanisms of the association and ultimate clinical utility is warranted.

KW - Cohort study

KW - Emergency department

KW - Hospitalization

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85018480979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018480979&partnerID=8YFLogxK

U2 - 10.2147/PGPM.S114211

DO - 10.2147/PGPM.S114211

M3 - Article

AN - SCOPUS:85018480979

VL - 10

SP - 39

EP - 47

JO - Pharmacogenomics and Personalized Medicine

JF - Pharmacogenomics and Personalized Medicine

SN - 1178-7066

ER -